drugset / Trial / NCT06192888
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
Phase 1
Active not recruiting
39 enrolled
Memorial Sloan Kettering Cancer Center
Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out whether the combination of glofitamab and lenalidomide is an effective treatment for relapsed or refractory Mantle Cell Lymphoma
Timeline
- Start
- 2024-01-08
- Primary completion
- 2028-01-08
- Completion
- 2028-01-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glofitamab | Monoclonal antibody | — | Intravenous |
| Subject | Lenalidomide | Other / unclassified | — | Oral |
| Background | Obinutuzumab | Monoclonal antibody | — | Intravenous |